Literature DB >> 20662003

Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.

Maria Peiris-Pagès1, Steven J Harper, David O Bates, Pramila Ramani.   

Abstract

Neuroblastoma (NB) is the second most common extracranial tumour of childhood. Angiogenesis plays a crucial role in the growth and development of NB and vascular endothelial growth factor (VEGF), one of the most potent stimuli of angiogenesis, has been studied extensively in vitro. VEGF(165) has been shown to be the predominant angiogenic isoform expressed in NB cell lines and tumours. In this study, we investigated the anti-angiogenic isoform of VEGF-A, generated from distal splice site selection in the terminal exon of VEGF (VEGF(165)b) and shown to be down-regulated in epithelial malignancies. The expression of both the pro- (VEGF(xxx)) and the anti-angiogenic (VEGF(xxx)b) isoforms was compared in a range of NB and ganglioneuroma (GN) tumours. Whereas VEGF(xxx)b and VEGF(xxx) were both expressed in GN, specific up-regulation of the VEGF(xxx) isoforms was seen in NB at RNA and protein levels. Highly tumourigenic NB cell lines also showed up-regulation of the angiogenic isoforms relative to VEGF(xxx)b compared to less tumourigenic cell lines, and the isoforms were differentially secreted. These results indicate that VEGF(165) is up-regulated in NB and that there is a difference in the balance of isoform expression from anti-angiogenic VEGF(165)b to angiogenic VEGF(165). Treatment with recombinant human VEGF(165)b significantly reduced the growth rate of established xenografts of SK-N-BE(2)-C cells (4.24 +/- 1.01 fold increase in volume) compared with those treated with saline (9.76 +/- 3.58, p < 0.01). Microvascular density (MVD) was significantly decreased in rhVEGF(165)b-treated tumours (19.4 +/- 1.9 vessels/mm(3)) in contrast to the saline-treated tumours (45.5 +/- 8.6 vessels/mm(3)). VEGF(165)b had no significant effect on the proliferative or apoptotic activity, viability or cytotoxicity of SK-N-BE(2)-C cells after 48 h. In conclusion, VEGF(165)b is an effective inhibitor of NB growth. These findings provide the rationale for further investigation of VEGF(165)b in NB and other paediatric malignancies. Copyright 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20662003      PMCID: PMC3287290          DOI: 10.1002/path.2746

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  34 in total

Review 1.  Angiogenesis as a target in neuroblastoma.

Authors:  Jochen Rössler; Melissa Taylor; Birgit Geoerger; Francoise Farace; Jeanette Lagodny; Regine Peschka-Süss; Charlotte M Niemeyer; Gilles Vassal
Journal:  Eur J Cancer       Date:  2008-07-07       Impact factor: 9.162

2.  The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts.

Authors:  Lova Segerström; Dieter Fuchs; Ulrika Bäckman; Kajsa Holmquist; Rolf Christofferson; Faranak Azarbayjani
Journal:  Pediatr Res       Date:  2006-09-20       Impact factor: 3.756

3.  A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2.

Authors:  S Cébe Suarez; M Pieren; L Cariolato; S Arn; U Hoffmann; A Bogucki; C Manlius; J Wood; K Ballmer-Hofer
Journal:  Cell Mol Life Sci       Date:  2006-09       Impact factor: 9.261

4.  Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.

Authors:  John M Maris; Joshua Courtright; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Lock; Mayamin Tajbakhsh; C Patrick Reynolds; Stephen T Keir; Jianrong Wu; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2008-07       Impact factor: 3.167

5.  Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.

Authors:  John M Maris; Joshua Courtright; Peter J Houghton; Christopher L Morton; Richard Gorlick; E Anders Kolb; Richard Lock; Mayamin Tajbakhsh; C Patrick Reynolds; Stephen T Keir; Jianrong Wu; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2008-03       Impact factor: 3.167

6.  p73 Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis.

Authors:  Raquel Díaz; Cristina Peña; Javier Silva; Yolanda Lorenzo; Vanesa García; José M García; Antonio Sánchez; Pablo Espinosa; Rosario Yuste; Félix Bonilla; Gemma Domínguez
Journal:  Int J Cancer       Date:  2008-09-01       Impact factor: 7.396

7.  Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease.

Authors:  Thomas L Sims; Regan F Williams; Cathy Y Ng; Shannon F Rosati; Yunyu Spence; Andrew M Davidoff
Journal:  Surgery       Date:  2008-08       Impact factor: 3.982

8.  Recombinant human VEGF165b protein is an effective anti-cancer agent in mice.

Authors:  Emma S Rennel; Maryam A Hamdollah-Zadeh; Edward R Wheatley; Anette Magnussen; Yvonne Schüler; Sara P Kelly; Ciara Finucane; David Ellison; Stephanie Cebe-Suarez; Kurt Ballmer-Hofer; Stephen Mather; Lorna Stewart; David O Bates; Steven J Harper
Journal:  Eur J Cancer       Date:  2008-07-24       Impact factor: 9.162

9.  The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.

Authors:  Es Rennel; E Waine; H Guan; Y Schüler; W Leenders; J Woolard; M Sugiono; D Gillatt; Es Kleinerman; Do Bates; Sj Harper
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

10.  VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

Authors:  A H R Varey; E S Rennel; Y Qiu; H S Bevan; R M Perrin; S Raffy; A R Dixon; C Paraskeva; O Zaccheo; A B Hassan; S J Harper; D O Bates
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

View more
  9 in total

1.  The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1.

Authors:  Magdalena Pruszko; Elisa Milano; Mattia Forcato; Sara Donzelli; Federica Ganci; Silvia Di Agostino; Simone De Panfilis; Francesco Fazi; David O Bates; Silvio Bicciato; Maciej Zylicz; Alicja Zylicz; Giovanni Blandino; Giulia Fontemaggi
Journal:  EMBO Rep       Date:  2017-06-26       Impact factor: 8.807

Review 2.  The role of VEGF 165b in pathophysiology.

Authors:  Maria Peiris-Pagès
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

3.  Identification of novel biomarkers in neuroblastoma associated with the risk for bone marrow metastasis: a pilot study.

Authors:  J Osman; S Galli; M Hanafy; X Tang; A Ahmed
Journal:  Clin Transl Oncol       Date:  2013-04-04       Impact factor: 3.405

Review 4.  Matrix metalloproteinase 14 modulates signal transduction and angiogenesis in the cornea.

Authors:  Jin-Hong Chang; Yu-Hui Huang; Christy M Cunningham; Kyu-Yeon Han; Michael Chang; Motoharu Seiki; Zhongjun Zhou; Dimitri T Azar
Journal:  Surv Ophthalmol       Date:  2015-12-02       Impact factor: 6.048

5.  VEGF spliced variants: possible role of anti-angiogenesis therapy.

Authors:  Caroline Hilmi; Mélanie Guyot; Gilles Pagès
Journal:  J Nucleic Acids       Date:  2011-10-13

Review 6.  Splicing Regulators and Their Roles in Cancer Biology and Therapy.

Authors:  Maria Roméria da Silva; Gabriela Alves Moreira; Ronni Anderson Gonçalves da Silva; Éverton de Almeida Alves Barbosa; Raoni Pais Siqueira; Róbson Ricardo Teixera; Márcia Rogéria Almeida; Abelardo Silva Júnior; Juliana Lopes Rangel Fietto; Gustavo Costa Bressan
Journal:  Biomed Res Int       Date:  2015-07-26       Impact factor: 3.411

7.  Development of a naringenin microemulsion as a prospective ophthalmic delivery system for the treatment of corneal neovascularization: in vitro and in vivo evaluation.

Authors:  Yu Ma; Jingjing Yang; Yali Zhang; Chunyan Zheng; Zhen Liang; Ping Lu; Fei Song; Yuwei Wang; Junjie Zhang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

Review 8.  How VEGF-A and its splice variants affect breast cancer development - clinical implications.

Authors:  Hivin Al Kawas; Inas Saaid; Paul Jank; Christina C Westhoff; Carsten Denkert; Therese Pross; Karoline Barbara Stephanie Weiler; Maria Margarete Karsten
Journal:  Cell Oncol (Dordr)       Date:  2022-03-18       Impact factor: 7.051

9.  Detection of VEGF-A(xxx)b isoforms in human tissues.

Authors:  David O Bates; Athina Mavrou; Yan Qiu; James G Carter; Maryam Hamdollah-Zadeh; Shaney Barratt; Melissa V Gammons; Ann B Millar; Andrew H J Salmon; Sebastian Oltean; Steven J Harper
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.